Immunosuppression, Shared Decisions

The contract between this chapter and the reader.

1. 1. Survey the immunosuppressants used across glomerular disease and their shared risks.
2. 2. Match immunosuppression intensity to disease severity and minimize exposure.
3. 3. Provide infection prophylaxis and vaccination.
4. 4. Address fertility and pregnancy in the young patient.
5. 5. Recognise the preference-sensitive treatment decisions.
6. 6. Apply shared decision-making.
7. 7. Recognise conservative care as a legitimate choice.
8. 8. Care for the whole patient beyond the kidney.
9. 9. Integrate the volume's approach to treating glomerular disease.

A sixty-second reading. Each bullet stands alone.

• The immunosuppressants used across glomerular disease share risks and demand monitoring.
• Infection is the leading early risk of immunosuppression and requires prophylaxis and vaccination.
• Immunosuppression intensity is matched to disease severity, minimizing cumulative exposure.
• Cyclophosphamide is gonadotoxic; fertility preservation and fertility-sparing agents are considered.
• Mycophenolate is teratogenic and is switched to azathioprine when pregnancy is planned.
• Latent infections (tuberculosis, hepatitis B) are screened and treated before certain agents.
• Many treatment decisions are genuinely preference-sensitive and hinge on the patient's values.
• Watchful waiting versus immunosuppression is a values-laden choice in lower-risk disease.
• Shared decision-making presents options and absolute risks and elicits the patient's goals.
• Conservative care is a legitimate choice, including non-dialytic care at kidney failure.
• The whole patient — cardiovascular risk, bone health, mental health, quality of life — is cared for.
• The biopsy informs the decision; the patient decides; the clinician partners.
• Treating glomerular disease means treating the person, not just the proteinuria.

The medical core. An expert should agree the cross-cutting decisions of treating glomerular disease are fully covered here.

Why it matters at the bedside

This volume has reached for immunosuppression again and again — and this closing chapter steps back to ask how to wield it wisely, and when to hold it. The drugs share risks that must be anticipated; many of the treat-or-not decisions are genuinely the patient's to make; and behind every biopsy is a person with a life, a fertility, and a set of values. Treating glomerular disease well is, in the end, treating the whole patient and deciding with them.

The shared immunosuppression toolkit and its risks

• A handful of agents recur throughout the volume: corticosteroids, cyclophosphamide, mycophenolate, calcineurin inhibitors, rituximab, and the newer drugs (belimumab, voclosporin, complement inhibitors, targeted-release budesonide). They share risks — infection (the dominant cause of early death in immunosuppressed glomerular disease, especially ANCA vasculitis and lupus) and long-term malignancy — alongside drug-specific toxicities: steroid toxicity, cyclophosphamide's gonadotoxicity and bladder and malignancy risk, calcineurin-inhibitor nephrotoxicity, mycophenolate's teratogenicity, and rituximab's risk of hepatitis B reactivation and PJP.

Matching intensity and minimizing exposure

• The governing principle is proportionality: match the intensity of immunosuppression to the severity of the disease, and use the lowest effective cumulative exposure. Aggressive, organ-threatening disease (proliferative lupus, crescentic GN) earns aggressive induction; milder or self-limiting disease does not. The modern direction — steroid-sparing, combination, lower-dose regimens — is all about delivering benefit while limiting the cumulative toll.

Infection prophylaxis and vaccination

• Because infection is the leading early hazard, prophylaxis and vaccination are integral. PJP prophylaxis (co-trimoxazole) covers significant immunosuppression; latent infections are screened and treated before certain agents (tuberculosis; hepatitis B before rituximab/anti-CD20, to prevent reactivation); vaccination is given before immunosuppression where possible, and live vaccines are avoided during it. Vigilance for infection runs throughout treatment.

Fertility, pregnancy, and the young patient

• Many patients with glomerular disease are young — lupus, IgA, FSGS — so fertility and pregnancy are central, not peripheral. Cyclophosphamide is gonadotoxic, so fertility preservation and fertility-sparing agents are considered; mycophenolate (and mTOR inhibitors) are teratogenic and are switched (to azathioprine) when pregnancy is planned. Pregnancy is planned around stable disease and safe drugs, with monitoring — a deliberate, shared decision rather than an afterthought.

The preference-sensitive decisions

• Across the volume, many decisions are genuinely values-laden rather than dictated by the biopsy: watchful waiting versus immunosuppression in lower-risk disease (membranous), how aggressively to treat, whether to treat a frail or elderly patient or choose conservative care, and — at kidney failure — transplant versus dialysis versus conservative care. These hinge on the patient's goals, values, and tolerance of risk and toxicity, and they are where shared decision-making belongs.

Shared decision-making

• Where equipoise is real, the clinician's job is to inform and partner, not to dictate: present the options, lay out the benefits and harms in absolute terms (natural frequencies), elicit the patient's values and goals, decide together, and check understanding (teach-back). This is not a softening of medicine but its proper practice when more than one reasonable path exists — and it is how the volume's many ‘it depends’ decisions are actually made.

Conservative care as a legitimate choice

• A recurring, important point: not treating, or treating less, can be the right choice. Conservative care — declining immunosuppression for a frail patient, or choosing non-dialytic care at kidney failure — is a legitimate, values-concordant path, not a failure. The supportive backbone continues regardless, and symptom and quality-of-life management come to the fore. Respecting this choice is part of treating the whole patient.

The whole patient

• Beyond the proteinuria sits a person carrying cardiovascular risk, bone and mineral consequences, the psychological burden of a chronic disease and its treatment, and a quality of life that immunosuppression can both protect and erode. Caring for the whole patient — cardiovascular and bone health, mental health, the burden of treatment, and what matters to them — is the frame in which every disease-specific decision sits.

The unifying message

• The volume resolves to a single ethic of practice: treat glomerular disease by matching immunosuppression to severity, protecting against its harms (infection, fertility, malignancy), and deciding with the patient wherever the choice is preference-sensitive. The biopsy informs the decision; the patient decides; the clinician partners. That — not any single drug or pattern — is what it means to treat glomerular disease well.

Five fully-built tables.

Table A — The immunosuppression toolkit

Table B — The shared and drug-specific risks

Table C — Prophylaxis and vaccination

Table D — Fertility and pregnancy

Table E — The preference-sensitive decisions

Visualise & Map

Numbered rules. These numbers are the cross-reference handle for the cases and flowcharts.

Clinical Reasoning

Five cases. Each stops you at a decision before it answers it.

Exhaustive. Every rule in the chapter is here.

Safety & Evidence

Panel A — Red flags

Panel B — NEVER DO

Anti-patterns clinicians fall into. Each becomes a Level 22 distractor.

The grade reflects strength of evidence, not importance.

Patient Decisions

Outcomes as natural frequencies. Figures are representative; the direction of effect is given where precise numbers are uncertain.

Decisions where more than one reasonable path exists and the patient's values should drive the choice.

• Watchful waiting vs immunosuppression. In lower-risk disease (e.g., membranous), spontaneous remission is common and immunosuppression carries real toxicity — the choice turns on the patient's tolerance of uncertainty versus toxicity.
• The intensity of immunosuppression. More aggressive regimens may offer more benefit at more harm — the right point on that trade depends on the patient's goals and risk tolerance.
• Treat vs conservative care. For a frail or elderly patient, declining or limiting immunosuppression may be the values-concordant choice.
• Transplant vs dialysis vs conservative care. At kidney failure, the modality (or none) is a major, values-laden decision.
• Fertility-affecting choices. Agent selection and timing weigh disease control against fertility and pregnancy plans.

Scripts for partnering with the patient where equipoise is real.

Script 1 — Treat or watch (lower-risk disease)

• Frame: “There are two reasonable paths here, and which is right depends on what matters to you.”
• Options + absolute risk: “About a third of people like you improve without treatment. Treatment can help, but carries real side-effects — here is roughly how the numbers compare.”
• Elicit values: “How do you feel about waiting and watching versus starting treatment now, given those trade-offs?”
• Decide together + teach-back: “Let's choose together — and can you tell me back how you understand the two options?”

Script 2 — Treat or conservative care (frail patient)

• Frame: “Aggressive treatment could help the kidney, but it carries real risks that matter more given your other health.”
• Options + absolute risk: “We can treat intensively, treat gently, or focus on comfort and supportive care — here is what each is likely to mean for you.”
• Elicit values + decide: “What matters most to you — doing everything for the kidney, or quality of life with less treatment? Let's decide together, and conservative care is a fully legitimate choice.”

Apply & Test

Copy-paste chart notes that map to the real decisions in this chapter.

Template 1 — Pre-immunosuppression checklist note

• Latent infection screening: tuberculosis; hepatitis B (before rituximab) ___.
• PJP prophylaxis arranged; other prophylaxis ___.
• Vaccination given before starting; live vaccines avoided ___.
• Fertility (young patient): preservation; fertility-sparing agents; pregnancy planning ___.
• Intensity matched to severity; cumulative-exposure plan ___.

Template 2 — Shared-decision / preference note

• Decision and whether it is preference-sensitive: ___.
• Options presented with absolute benefits/harms: ___.
• Patient's values, goals, and risk tolerance elicited: ___.
• Decision reached together; teach-back confirmed: ___.
• Conservative care offered where appropriate; whole-patient needs (CV, bone, mental health, QoL): ___.

Pre-rounds compression. Rules only.

Active recall. At least one card per objective.

Micro-teaching for rounds. Two scenarios, five steps each.

Metacognition anchored to this chapter's tensions. No answers provided.

1. 1. Where equipoise is genuine, how do you offer a real choice without abdicating your responsibility to guide — and without letting your own preference masquerade as the evidence?
2. 2. Immunosuppression's harms are statistical and future, its benefits often uncertain; how do you convey that honestly without either frightening or falsely reassuring the patient?
3. 3. When a frail patient declines treatment you believe could help the kidney, how do you honour their choice while being sure they understood it?
4. 4. Fertility, pregnancy, and the long arc of a young life can matter more to a patient than a creatinine; how do you weight what matters to them against what matters to the kidney?
5. 5. Across this whole volume, when does ‘treating the disease’ and ‘treating the patient’ diverge — and which, in the end, is your job?

Nine items, each anchored in this chapter. At least one per objective.